Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Following recent updates from numerous management teams within the health care space, Needham analyst Ami Fadia has reevaluated the stocks in the firm's coverage universe using a stock selection criteria and a risk-reward matrix.
Let’s examine the firm’s strongest reward/risk picks:
Bicycle Therapeutics PLC (NASDAQ:BCYC)
Needham maintains Buy rating with $85 price target
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- Fadia is positive on the lead nectin-4 asset BT8009, which “demonstrated promising early Phase 1/2 data in urothelial cancer”; sees emerging safety differentiation while “efficacy is comparable to Padcev so far.”
- The analyst sees the potential to “deepen oncology pipeline and applications beyond oncology” due to “high throughput screen platform using phage display,” which assists lead identification.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Needham maintains Buy rating with $215 price target
- “[The] Oxybate franchise is more sustainable than investors appreciate,” with expectations of “minimal erosion of the Xywav volume at least in the near term,” Fadia said.
- The analyst highlights future growth due to “newly approved indication Tuberous Sclerosis Complex and off-label use” and attributes recent quarterly growth slumps “due to saturation in Dravet Syndrome and Lennox-Gastaut Syndrome markets.”
Sage Therapeutics Inc. (NASDAQ:SAGE)
Needham maintains Buy rating with $85 price target
- Fadia said “upcoming data readouts for SAGE-217 are relatively de-risked,” and the analyst expects the Phase 3 study to hit the primary endpoint of HAM-D decrease at day 3 “as SAGE-217 has demonstrated statistically significant separation from placebo at day 2/3.”
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.